Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
- PMID: 29437588
- DOI: 10.1182/blood-2017-11-818286
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
Abstract
Ibrutinib has revolutionized the management of chronic lymphocytic leukemia and is now being increasingly used. Although considered to be less immunosuppressive than conventional immunochemotherapy, the observation of a few cases of invasive fungal infections in patients treated with ibrutinib prompted us to conduct a retrospective survey. We identified 33 cases of invasive fungal infections in patients receiving ibrutinib alone or in combination. Invasive aspergillosis (IA) was overrepresented (27/33) and was associated with cerebral localizations in 40% of the cases. Remarkably, most cases of invasive fungal infections occurred with a median of 3 months after starting ibrutinib. In 18/33 cases, other conditions that could have contributed to decreased antifungal responses, such as corticosteroids, neutropenia, or combined immunochemotherapy, were present. These observations indicate that ibrutinib may be associated with early-onset invasive fungal infections, in particular IA with frequent cerebral involvement, and that patients on ibrutinib should be closely monitored in particular when other risk factors of fungal infections are present.
© 2018 by The American Society of Hematology.
Comment in
-
Ibrutinib and fungus: an invasive concern.Blood. 2018 Apr 26;131(17):1882-1884. doi: 10.1182/blood-2018-02-832154. Blood. 2018. PMID: 29699994 No abstract available.
Similar articles
-
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.Mycoses. 2019 Dec;62(12):1140-1147. doi: 10.1111/myc.13001. Epub 2019 Oct 22. Mycoses. 2019. PMID: 31520441
-
Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report.Clin Microbiol Infect. 2018 Jul;24(7):785-786. doi: 10.1016/j.cmi.2018.01.028. Epub 2018 Feb 7. Clin Microbiol Infect. 2018. PMID: 29427802 No abstract available.
-
Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook.J Oncol Pharm Pract. 2019 Sep;25(6):1486-1490. doi: 10.1177/1078155218788717. Epub 2018 Jul 25. J Oncol Pharm Pract. 2019. PMID: 30045683
-
Ibrutinib induced acute tubular injury: A case series and review of the literature.Am J Hematol. 2019 Sep;94(9):E223-E225. doi: 10.1002/ajh.25546. Epub 2019 Jun 17. Am J Hematol. 2019. PMID: 31148235 Review. No abstract available.
-
Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.J Oncol Pharm Pract. 2018 Oct;24(7):544-549. doi: 10.1177/1078155217718617. Epub 2017 Jul 16. J Oncol Pharm Pract. 2018. PMID: 28714377 Review.
Cited by
-
Paradoxal Trends in Azole-Resistant Aspergillus fumigatus in a National Multicenter Surveillance Program, the Netherlands, 2013-2018.Emerg Infect Dis. 2020 Jul;26(7):1447-1455. doi: 10.3201/eid2607.200088. Emerg Infect Dis. 2020. PMID: 32568033 Free PMC article.
-
A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy.Med Mycol Case Rep. 2019 Dec 5;27:17-21. doi: 10.1016/j.mmcr.2019.12.007. eCollection 2020 Mar. Med Mycol Case Rep. 2019. PMID: 31879587 Free PMC article.
-
Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations.Ther Adv Hematol. 2022 Aug 9;13:20406207221116577. doi: 10.1177/20406207221116577. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35966045 Free PMC article. Review.
-
Invasive Fusariosis in Patients with Hematologic Diseases.J Fungi (Basel). 2021 Sep 28;7(10):815. doi: 10.3390/jof7100815. J Fungi (Basel). 2021. PMID: 34682236 Free PMC article. Review.
-
Promises and pitfalls of targeted agents in chronic lymphocytic leukemia.Cancer Drug Resist. 2020 May 23;3(3):415-444. doi: 10.20517/cdr.2019.108. eCollection 2020. Cancer Drug Resist. 2020. PMID: 35582452 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
